Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.

M & A Cancer Companies

Eight Things To Know From Novartis' Third Quarter Call

The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of drugs like Cosentyx, Kymriah, Kisqali and Aimovig underway, there was a lot for Novartis' management team to address.

Sales & Earnings Launches Business Strategies

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded. 

ImmunoOncology Clinical Trials Commercial
Advertisement


 Recent Tweets from Scrip


Case Study: Broad Thinking Yields Big Results

There are numerous details when considering product packaging that require both creative thinking and feature prioritization. Rather than developing a standard solution for the current need, it’s imperative to think broadly and design options that are cost-effective, simplify operations and save time and/or resources.

Read Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

 

Commercial Explore this Topic

Set Alert for Commercial

Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

Companies Commercial Business Strategies

A Long March After Approval: What You Need To Launch Orphan Drugs In China

Without automatic reimbursement in place, makers of orphan and rare disease drugs must look at innovative alternative ways to make their high-priced new therapies accessible to patients in China.

China Business Strategies Commercial

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

Every Little Helps: Shire Product Advances Fortify Takeda's Bid

A positive opinion in the EU for Shire's Takhzyro and a favorable US advisory committee vote for prucalopride are incremental positives for Takeda's planned acquisition, on which shareholders are likely to vote in the coming weeks.

Advisory Committees Approvals

CDMO Space In Focus As Piramal Mulls Sale

As the Indian business conglomerate Piramal considers the sale of its contract development and manufacturing organization (CDMO), some experts say that more CDMO players could potentially join the sale line up in a fragmented sector but one that’s in demand.
Commercial Deals

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.

Deals Liver & Hepatic

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Leadership Companies

Roche Says MS Drug Ocrevus Launch Its 'Best So Far', Vows To Help US Reform

Roche said MS drug Ocrevus should generate sales of CHF2bn in its first full year after launch. The Swiss group also pledged to actively help the Trump Administration with its healthcare reform program.

Sales & Earnings Companies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Pfizer Expands In Breast Cancer With Talazoparib Approval

The PARP inhibitor, acquired with Medivation, will launch in a field where Pfizer already has commercial experience through its CDK4/6 inhibitor Ibrance. 
Approvals Launches Cancer

Every Little Helps: Shire Product Advances Fortify Takeda's Bid

A positive opinion in the EU for Shire's Takhzyro and a favorable US advisory committee vote for prucalopride are incremental positives for Takeda's planned acquisition, on which shareholders are likely to vote in the coming weeks.

Advisory Committees Approvals

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Leadership Companies

Vertex’s Danish Reimbursement Deal Brings Budget Predictability

Vertex’s portfolio-based access deal in Denmark will give patients quicker access to a range of cystic fibrosis drugs and give budget predictability to the company and government.

Europe Denmark

Research & Development Explore this Topic

Set Alert for Research & Development

UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

The anti-FcRn MAb, rozanolixizumab, has been found to be effective in myasthenia gravis and has potential in ITP, but other companies are also developing potential therapeutic candidates for such auto-immune conditions.

 

Neurology Clinical Trials Research & Development

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.

Deals Liver & Hepatic

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.

Pricing Strategies Reimbursement

Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership

Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.

Deals Intellectual Property
UsernamePublicRestriction

Register

Advertisement